Use of metformin in pediatric age

Baratto, Claudia; Fintini, Danilo; Nobili, Valério; Patera, Patrizia Ippolita; Cappa, Marco; Brufani, M.

doi:10.1111/j.1399-5448.2010.00741.x

Cited by 22 publications

(25 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, there will be some misclassification from prescriptions for patients with PCOS, pre-diabetes and the metabolic syndrome [17-19]. Some women of reproductive age who are treated with metformin are probably suffering from PCOS rather than diabetes.…”

Section: Discussionmentioning

confidence: 99%

No increase in new users of blood glucose-lowering drugs in Norway 2006–2011: a nationwide prescription database study

et al. 2014

View full text Add to dashboard Cite

BackgroundNational estimates for the occurrence of diabetes are difficult to obtain, particularly time trends in incidence. The aim was to describe time trends in prevalent and incident use of blood glucose-lowering drugs by age group and gender in Norway during 2005–2011.MethodsData were obtained from the nationwide Norwegian Prescription Database. We defined prevalent users of “insulins only” as individuals having no oral antidiabetic drugs (OAD) dispensed from a pharmacy during the previous 24 months or in the subsequent 12 months. Incident users had no blood glucose-lowering drugs dispensed in the previous 24 months; incident “insulins only” users also had no OAD in the subsequent 12 months.ResultsIn 2011, 3.2% of the population had blood glucose-lowering drugs dispensed, and the incidence rate was 313 per 100,000 person years. The prevalence of OAD use increased from 1.8% in 2005 to 2.4% in 2011; however a decreasing trend in incidence of OAD use was observed, particularly in those aged 70 years and older. In 2010, 0.64% of the population had insulins only dispensed, with an overall incidence rate in the total population of 33 per 100,000 person years which was stable over time.ConclusionsIn this nationwide study, we found that although the prevalent use of OAD had increased in recent years, incident use was stable or had decreased. This may indicate that the increase in diabetes occurrence in Norway is levelling off, at least temporarily.

show abstract

Section: Discussionmentioning

confidence: 99%

No increase in new users of blood glucose-lowering drugs in Norway 2006–2011: a nationwide prescription database study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Met's lack of effect on metabolic variables is likely due to the insufficient time and dose used in this study. However, although this drug is prescribed to improve the metabolic states of patients afflicted with DT2 or polycystic ovary syndrome , a higher dose was not used because it has not been sufficiently studied in obese individuals <12 yr of age with IR . On the basis of the results of previous studies, we speculate that a higher dose of Met could have improved IR .…”

Section: Discussionmentioning

confidence: 99%

Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Metformin therapy in adolescents affected by T2DM is well established [8], although recent data from the TODAY study (Treatment Options for T2DM in Adolescents and Youth) [9] have showed discouraging results: 52% of adolescents with recent-onset T2DM treated with metformin alone manifested treatment failure within few years after diagnosis, implying that most youth with T2DM will require multiple oral agents or insulin therapy shortly after diagnosis.…”

Section: Introductionmentioning

confidence: 99%

“…It is currently the most widely used drug worldwide for the treatment of T2DM in adults. Its primary action appears to be the inhibition of hepatic glucose production and the increase in peripheral insulin sensitivity [7,8] (fig. 1).…”

Section: Introductionmentioning

confidence: 99%

Systematic Review of Metformin Use in Obese Nondiabetic Children and Adolescents

et al. 2013

Self Cite

View full text Add to dashboard Cite

Objective: Childhood obesity has become epidemic and has been accompanied by an increase in prevalence of type 2 diabetes (T2DM) in youth. Addressing obesity and insulin resistance by drug treatment represents a rational strategy for the prevention of T2DM. A systematic review was performed to evaluate the effectiveness of metformin in reducing weight and ameliorating insulin resistance in obese nondiabetic children. Methods: A PubMed database search was conducted, using ‘metformin', ‘obesity', ‘insulin resistance', ‘children', ‘adolescents' as search terms. Results: Eleven trials were included in the present review. Metformin was administered for 6-12 months at a dosage of 1,000-2,000 mg/daily, decreasing BMI by 1.1-2.7 compared with placebo or lifestyle intervention alone. Concomitantly, fasting insulin resistance improved after metformin therapy. Posttreatment follow-up was performed in one study, showing that after 1 year of discontinuation of therapy the decrease in BMI disappears. Conclusions: Short-term metformin treatment appears to moderately affect weight reduction in severely obese children and adolescents, with a concomitant improvement in fasting insulin sensitivity. Further studies with longer treatment period are needed to establish how much metformin can reduce weight and its real utility in preventing T2DM development in pediatric patients.

show abstract

Use of metformin in pediatric age

Abstract: Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Use of metformin in pediatric age.

Cited by 22 publications

References 66 publications

No increase in new users of blood glucose-lowering drugs in Norway 2006–2011: a nationwide prescription database study

No increase in new users of blood glucose-lowering drugs in Norway 2006–2011: a nationwide prescription database study

Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents

Systematic Review of Metformin Use in Obese Nondiabetic Children and Adolescents

Contact Info

Product

Resources

About